CURE SYNGAP1 (fka SynGAP Research Fund), a 501(c)(3) patient-led organization, has announced a $53,569.00 grant to Dr. Ryan Dhindsa, MD, PhD, of Baylor College of Medicine. This grant is part of a broader biomarker project initiated by CURE SYNGAP1 aimed at revolutionizing the diagnosis and treatment of SYNGAP1-Related Disorders (SRD).

A smartphone app designed to tackle the underlying psychological causes of premature ejaculation can significantly improve sex life and delay ejaculation, while offering a way to reduce stigma around the condition, say researchers.

In a study published March 5 in Science, Ke Cheng and his colleagues describe a therapy designed to enhance the heart’s own ability to protect and repair itself after injury. Cheng’s innovation in drug delivery points to a future where RNA therapy allows the body to produce its own medicine targeted at specific organs. 

Engineers at Duke University have demonstrated a technique that uses microbubbles and ultrasound to help relatively large cancer drugs enter tumor cells and cause them to self-destruct.

Insilico Medicine, under the stock code HKEX: 3696, has been officially included as a constituent stock of the Hang Seng Composite Index (HSCI), and the company's shares are now eligible for trading via the Stock Connect program including Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect, the channels for stock trading and investment between capital market investors in Hong Kong and Chinese Mainland. Insilico’s inclusion in the Stock Connect program will allow qualified Chinese Mainland investors to trade directly, which is expected to further enhance stock liquidity and market attention, strengthen the company's capital market influence, and provide more solid support for continued innovation and sustainable development.

A research team led by Albert Einstein College of Medicine scientists has developed a new strategy to engineer immune cells that dramatically prolongs their effectiveness after being infused into patients to fight cancer and HIV, addressing a major limitation of current treatments. Their findings, published today in Science Advances, describe a manufacturing approach that, compared to the existing process, generates longer-lasting immune cells that provide more sustained control of human blood cancers and suppression of HIV-infection in mouse models.

Scientists in Sweden and the U.S. today reported the first-ever direct observation a type of short‑lived molecule that has shaped decades of thinking in atmospheric chemistry, combustion research and biomedical science.

 

Publishing in Science Advances, researchers from KTH Royal Institute of Technology, in Stockholm, and Kinetic Chemistry Research in Mountain View, California, say their discovery of long-theorized, oxygen-rich tetroxides has implications in a number of sciences, including atmospheric chemistry, biochemistry and medicine and combustion chemistry.